# Respiratory Agents: Monoclonal Antibodies-Anti-IL/Anti-IgE

## Length Of Authorizations

365 Days

## Clinical Criteria For Asthma

- Indicated for **moderate to severe asthma** if:
  
  - Prescribed by or in consultation with an allergist/immunologist or pulmonologist
  - Preferred medications will be approved for patients with uncontrolled eosinophilic asthma symptoms and/or exacerbations despite at least 30 days adherence to therapy with:

    - Medium dose preferred ICS/LABA inhaler (patients 6-11 years old) – Nucala only
    - Medium dose preferred ICS/LABA inhaler with tiotropium or high dose preferred ICS/LABA inhaler (patients 12 years and older) – Nucala or Fasenra

  - Non-preferred medications will be approved for patients with uncontrolled eosinophilic asthma symptoms and/or exacerbations despite at least 90 days adherence to therapy with a preferred agent

## Additional Criteria For Dupilumab (Dupixent)

- Indicated for **moderate to** **severe atopic dermatitis** if:

  - Patient has minimum body surface area (BSA) involvement of at least 10%
  - Prescribed by or in consultation with a dermatologist or allergist/immunologist
  - Patient is 6 years of age or older
  - Patient has had inadequate response or contraindication to two of the following: topical corticosteroids, topical calcineurin inhibitors [e.g. Elidel], or topical PDE-4 inhibitors [e.g. Eucrisa™] unless atopic dermatitis is severe and involves greater than 25% of BSA.
  - Initial authorization is limited to 112 days with re-authorization of up to 365 days granted following demonstration of improvement in patient condition with therapy (e.g. reduced BSA affected).

- Indicated for **chronic rhinosinusitis with nasal polyposis** if:

  - Patient is 18 years of age or older
  - Patient had an inadequate response, intolerance or contraindication to one oral corticosteroid
  - Patient had a 30-day trial and experienced an inadequate response, intolerance or contraindication to one nasal corticosteroid spray

## Additional Criteria For Omalizumab (Xolair)

- Indicated for **chronic** **urticaria** if:

  - Patient has tried and failed two 14-day trials with two different antihistamines
  - Prescribed by or in consultation with a dermatologist or allergist/immunologist
  - Prescribed in accordance with its FDA approved labeling

- Indicated for **chronic rhinosinusitis with nasal polyposis** if:

  - Patient is 18 years of age or older
  - Patient had an inadequate response, intolerance or contraindication to one oral corticosteroid
  - Patient had a 30-day trial and experienced an inadequate response, intolerance or contraindication to one nasal corticosteroid spray

## Monoclonal Antibodies-Anti-IL/Anti-IgE

Respiratory Agents: Monoclonal Antibodies-Anti-IL/Anti-IgE

| PREFERRED | NON-PREFERRED |
| :--- | ---: |
| Fasenra PA | Dupixent |
| Nucala PA  |          |
| Xolair PA  |          |

### Link to Criteria

[Respiratory Agents: Monoclonal Antibodies - Anti-IL/Anti-IgE](https://pharmacy.medicaid.ohio.gov/sites/default/files/20220415_UPDL_Criteria_FINAL_.pdf#page=93)
